Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
International Sweetene...International Sweetener Colloquium
Not Confirmed
Not Confirmed
22-25 February, 2026
Not Confirmed
Not Confirmed
23-25 February, 2026
Clinical Trial Supply ...Clinical Trial Supply Europe
Not Confirmed
Not Confirmed
24-25 February, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
International Sweetener Colloquium
Not Confirmed
Contact SupplierInternational Sweetener Colloquium
International Sweetene...International Sweetener Colloquium
Industry Trade Show
Not Confirmed
22-25 February, 2026
Industry Trade Show
Not Confirmed
23-25 February, 2026
Clinical Trial Supply ...Clinical Trial Supply Europe
Industry Trade Show
Not Confirmed
24-25 February, 2026
Digital content
NEWS #PharmaBuzz
18 Feb 2025
// ECONOMICTIMES
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-lifesciences-inks-licensing-pact-with-zhuhai-for-cancer-drug/articleshow/118246495.cms
Drugs in Development
Details:
Beihai Biotech will be responsible for the manufacturing and supply of Beizray (docetaxel) while Zydus will be responsible for commercialisation in the US.
Lead Product(s): Docetaxel
Therapeutic Area: Oncology Brand Name: Beizray
Study Phase: Approved FDFProduct Type: Cytotoxic Drug
Sponsor: Zydus Lifesciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 14, 2025
Lead Product(s) : Docetaxel
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Zydus Lifesciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Zydus Lifesciences Inks Licensing Pact with Zhuhai For Cancer Drug
Details : Beihai Biotech will be responsible for the manufacturing and supply of Beizray (docetaxel) while Zydus will be responsible for commercialisation in the US.
Product Name : Beizray
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
February 14, 2025
Details:
BH011 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Urinary Bladder Neoplasms.
Lead Product(s): BH011
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 13, 2024
Lead Product(s) : BH011
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BH011 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Urinary Bladder Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 13, 2024
Details:
BH006 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): BH006
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 24, 2024
Lead Product(s) : BH006
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
An Relative Bioavailability Study of BH006 for Injection in Healthy Subjects
Details : BH006 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 24, 2024
Details:
BH009 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Lead Product(s): BH009
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 31, 2024
A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian Cancer
Details : BH009 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 31, 2024
Details:
BH002 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Lead Product(s): CAS 139306-10-8
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 30, 2024
Lead Product(s) : CAS 139306-10-8
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase I Clinical Trial of BH002 in Patients With Advanced Solid Tumors
Details : BH002 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 30, 2024
Details:
Docetaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Neoplasms.
Lead Product(s): Docetaxel
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Cytotoxic Drug
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 17, 2021
A Bioequivalence Study of Docetaxel Injection in Patients With Solid Tumours
Details : Docetaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
May 17, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
